Ciliary neurotrophic factor (CNTF) is a promising candidate for the
treatment of neurodegenerative or metabolic diseases, but suffers rapid
clearance in body. Here in this project, we constructed a new long-acting recombinant human
CNTF (rhCNTF) by genetic fusion with an albumin-binding domain (ABD) through a
flexible peptide linker, hoping to endow the new molecule prolonged serum
circulation time by binding with endogenous human serum albumin (HSA) and then
utilizing the naturally long-half-life property of HSA.